Participating Companies

AM-Pharma B.V.
Raised $195M in equi­ty and debt in 2019/2020 af­ter re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed ro­bust sig­ni­f­i­cant im­prove­ment of 40%+ OS in re­cAP group. TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts Q1 2022. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023, or as ear­ly as 2022 based on in­ter­im anal­y­s­es. [more in­for­ma­tion]
Anima Biotech
We de­vel­op a pipe­line across ther­a­peu­tic ar­eas and part­n­er with Phar­ma for their tar­gets in­clud­ing our $1B+ col­lab­o­ra­tion with Lil­ly for the dis­cov­ery and de­vel­op­ment of trans­la­tion in­hibi­tors of sev­er­al tar­gets. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Apic Bio
De­vel­op­er of a gene ther­a­py pro­pri­e­tary plat­form in­tend­ed to treat rare dis­eas­es with com­plex mech­anisms. The com­pany's plat­form of­fers APB-101 which tar­gets the liv­er by way of an AAV de­liv­ered Du­al Func­tion Vec­tor, en­abling doc­tors to treat rare, de­v­as­tat­ing neu­ro­log­i­cal and liv­er dis­eas­es. [more in­for­ma­tion]
AsclepiX Therapeutics
AX­T107 de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els that is su­pe­ri­or to stan­dard of care Eylea. [more in­for­ma­tion]
ATAI Life Sciences AG
ATAI is a glob­al biotech com­pany builder that lev­er­ages a de­cen­tral­ized, tech­nol­o­gy- and da­ta-driv­en plat­form mod­el to serve mil­lions of peo­ple suf­fer­ing from men­tal health di­s­or­ders. ATAI is com­mitt­ed to ac­quir­ing and ef­fi­cient­ly de­vel­op­ing in­no­va­tive treat­ments that ad­dress sig­ni­f­i­cant un­met med­i­cal needs and lead to paradigm shifts in the men­tal health space. [more in­for­ma­tion]
AUM Biosciences
AUM is a glob­al bio­phar­ma­ceu­ti­cal com­pany aim­ing to de­moc­ra­tize R&D with a fo­cus on dis­cov­er­ing, ac­quir­ing, and de­vel­op­ing nov­el ther­a­peu­tics in on­col­o­gy. [more in­for­ma­tion]
Axial Biotherapeutics, Inc.
The com­pany's bio­ther­a­peu­tics prod­ucts har­ness the gut-brain axis to de­vel­op nov­el Cen­tral Ner­vous Sys­tem (CNS) Ther­a­peu­tics to im­prove the qual­i­ty of life for peo­ple with CNS dis­eas­es and di­s­or­ders, pro­vid­ing med­i­cal pro­fes­sio­n­als and health­care in­sti­tu­tions with a new ap­proach for di­ag­nos­ing and treat­ing PD and ASD and po­ten­tial­ly other CNS dis­eas­es. [more in­for­ma­tion]
Azitra
The com­pany lev­er­ages mi­cro­bi­o­log­i­cal bac­te­ria strains tech­nol­o­gy to fa­cil­i­tate the treat­ment of ecze­ma, ichthyo­sis vul­garis, in­flam­ma­to­ry skin, ir­ri­tat­ed skin and or­phan skin dis­eas­es in­clud­ing Nether­ton syn­drome, en­abling der­ma­tol­o­gists to treat pa­tients with chron­ic and acute skin di­s­or­ders [more in­for­ma­tion]
Boundless Bio
De­vel­op­er of nov­el can­cer ther­a­peu­tics in­tend­ed to un­der­s­tand and treat in­trace­able can­cers. The com­pany is in the pro­cess of de­vel­op­ing a nov­el class of can­cer drugs and ex­trachro­mo­so­mal DNA (ecD­NA) that elim­i­nates can­cer cells abil­i­ty to em­ploy ecD­NA to sur­vive, en­abling health­care pro­fes­sio­n­als to treat most-dif­fi­cult can­cers. [more in­for­ma­tion]
CalciMedica
Fo­cused on CRAC chan­nel for the treat­ment of acute and se­vere in­flam­ma­to­ry dis­eas­es. CalciMed­i­ca’s lead com­pound Aux­o­ra has de­liv­ered promis­ing Phase 2 re­sults in se­vere COVID-19 pneu­mo­nia and acute pan­cre­ati­tis. A Phase 2/3 clin­i­cal trial of Aux­o­ra in up to 400 pa­tients with se­vere COVID-19 pneu­mo­nia is on­go­ing, and a Phase 2b trial of Aux­o­ra in pa­tients with acute pan­cre­ati­tis and a dose es­ca­lat­ing phase 2 study in ven­ti­lat­ed ARDS pa­tients with COVID-19 and other pneu­mo­nia are ex­pect­ed to com­mence soon. [more in­for­ma­tion]
Candesant Biomedical
Can­de­sant Biomed­i­cal is de­vel­op­ing a com­pelling prod­uct to un­lock the po­ten­tial of the sweat con­trol mar­ket. Fur­ther, the prod­uct will pro­vide a great val­ue to the con­sumer with an eco­nom­ic in­cen­tive to the treat­ing physi­cians. [more in­for­ma­tion]
Cellestia Biotech AG
Celles­tia Biotech AG is a pri­vate­ly-owned clin­i­cal-stage com­pany de­vel­op­ing in­no­va­tive first-in-class ther­a­pies to con­trol and mo­d­u­late patho­genic gene ex­pres­sion in mul­ti­ple dis­ease ar­eas by se­lec­tive in­hi­bi­tion of tran­scrip­tion fac­tors in the cell nu­cleus. [more in­for­ma­tion]
CerSci Therapeutics
De­vel­op­ing a new gen­er­a­tion of non-opi­oid medicines to treat acute post-op­er­a­tive and chron­ic neu­ro­path­ic pain. Lead pro­gram in Phase 1 (MAD/SAD/Food Ef­fect), CT-044, tar­get­ing re­ac­tive spe­cies that cause neu­ro­n­al ion chan­nel hy­per-sen­si­ti­za­tion, known to trig­ger pain. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Diasome
De­vel­op­er of nov­el and cell tar­get­ed ther­a­pies de­signed to treat di­a­betes, obe­si­ty and other metabolic con­di­tions. The com­pany's ther­a­pies in­clude ISLE-1 (In­Sulin Liv­er Ef­fect) Phase 2b study of HDV-In­sulin in sub­jects with Type 1 di­a­betes, en­abling pa­tients to get nov­el pro­pri­e­tary liv­er tar­get­ed in­sulins for both Type 1 and Type 2 di­a­betes eas­i­ly. [more in­for­ma­tion]
Enterin
De­vel­op­er of nov­el drugs in­tend­ed to re­pair the dys­func­tio­n­al gut-brain axis. The com­pany's drugs dis­places &al­pha;-synu­clein ag­gre­gates and re­s­tores nor­mal sig­nal­ing be­tween the gut and the brain, en­abling pa­tients with Parkin­son's dis­ease and other neu­rode­gen­er­a­tive con­di­tions to have a bet­ter the qual­i­ty of life. [more in­for­ma­tion]
EOC Pharma
EOC is a Shang­hai-based bio­phar­ma­ceu­ti­cal com­pany that is fo­cused on the in-li­cens­ing of in­no­va­tive glob­al on­col­o­gy prod­ucts, and de­vel­op­ing, man­u­fac­tur­ing and com­mer­cial­iz­ing them for the Chi­na mar­ket. [more in­for­ma­tion]
Faraday Pharmaceuticals
Chron­ic and acute agents to pre­vent car­di­ac and skele­tal mus­cle loss by mo­d­u­lat­ing neu­ro­hu­mo­ral path­ways and res­tor­ing metabolic flex­i­bil­i­ty: lead can­di­date FDY-5301 Ph 3 ready for reper­fu­sion in­jury fol­low­ing heart at­tack (AMI). $57M raised to date from Arch Ven­ture Part­n­ers, Po­laris Part­n­ers, WRF, Os­age [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
HemoShear Therapeutics
He­moS­hear Ther­a­peu­tics dis­cov­ers nov­el bi­o­log­i­cal tar­gets and ad­vances drug pro­grams to treat metabolic di­s­or­ders with sig­ni­f­i­cant un­met pa­tient need. The Com­pany's lead pro­grams in pro­pi­on­ic and methyl­malon­ic acidemia (rare in­born er­rors of metabolism) will en­ter phase 2 studies this year. [more in­for­ma­tion]
Incysus Therapeutics
The com­pany's ser­vices fo­cus on uti­l­iz­ing ge­net­i­cal­ly mod­i­fied gam­ma-del­ta T cells across a Drug Re­sis­tance Im­munother­a­py (DRI) plat­form that ad­dress­es the chal­lenges faced while tar­get­ing cold, low mu­ta­tion can­cers, en­abling the tar­get­ing of ma­lig­nant cells and po­ten­tial­ly more ef­fec­tive treat­ments for pa­tients with dif­fi­cult-to-treat solid tu­mor can­cers. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
jCyte
De­vel­op­er of cell-based tech­nol­o­gy in­tend­ed to cure re­tini­tis pig­men­tosa. The com­pany's ther­a­py used reti­nal pro­gen­i­tor cells can se­crete growth fac­tors to res­cue da­m­aged reti­nal cells which helps in treat­ing a de­gen­er­a­tive eye dis­ease that ul­ti­mate­ly caus­es blind­ness en­abling, pa­tients af­flict­ed by con­di­tions that lead to blind­ness, pre­serve and re­s­tore sight. [more in­for­ma­tion]
Juvenescence
De­vel­op­er of ther­a­pies and tech­nolo­gies de­signed to treat dis­eas­es of ag­ing and in­crease hu­man longevi­ty. The com­pany's tech­nolo­gies help pa­tients to erad­i­cate life-shat­ter­ing dis­eas­es that cause peo­ple to suf­fer un­til death, en­abling pa­tients to halt or po­ten­tial­ly re­v­erse el­e­ments of age­ing. [more in­for­ma­tion]
KAHR
The com­pany lead prod­uct, DSP107, is a CD47-41BB tar­get­ing com­pound that si­mul­ta­ne­ous­ly tar­get can­cer cells, weak­en their in­nate de­fens­es and ac­ti­vate an ef­fec­tive, lo­cal re­sponse of both in­nate (by block­ing ‘Don’t eat me’ sig­nals) and adap­tive im­mu­ni­ty (by pro­vid­ing co-sti­m­u­la­tion sig­nal to T and NK cells). [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Maverick Therapeutics
Mav­er­ick Ther­a­peu­tics is a biotech com­pany fo­cused on im­prov­ing the lives of pa­tients with solid tu­mor can­cers by de­vel­op­ing break­through T cell im­munother­a­pies with im­proved safe­ty and ef­fi­ca­cy. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPARg ag­on­ist, lerigl­i­ta­zone, de­mon­s­trat­ed clin­i­cal ben­e­fit of sig­ni­f­i­cant­ly re­duc­ing pro­gres­sion of cere­bral le­sions and myelo­pa­thy symp­toms in piv­o­tal Phase 2/3 study re­sults in X-ALD pts w Adreno­myeloneu­ro­pa­thy (AMN), 6MWT end­point was not met; on­go­ing dis­cus­sions with reg­u­la­tors re: ap­pro­val. Phase 2 da­ta in Frie­drich’s Ataxia showed mo­d­u­la­tion of the Fra­taxin path­way and res­to­ra­tion of the bioen­er­get­ics de­fic­its in FR­DA pa­tients. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Neurana Pharmaceuticals
The pri­mary ob­jec­tive of the study was to as­sess the ef­fi­ca­cy of vari­ous dai­ly dos­es of tolperi­sone to de­ter­mine the dose to be used for the planned Phase 3 clin­i­cal pro­gram. Giv­en the pos­i­tive re­sults of the STAR Study, Neu­ra­na plans to conduct an end-of-Phase 2 meet­ing with the FDA in the first quar­ter of 2020 and ini­ti­ate Phase 3 clin­i­cal studies of tolperi­sone lat­er in 2020. [more in­for­ma­tion]
NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (Jan 2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]
Notch Therapeutics
Notch’s tech­nol­o­gy plat­form us­es ge­net­i­cal­ly tailored stem cells as a re­ne­w­able source for cre­at­ing al­lo­gene­ic T cell ther­a­pies that ex­pand treat­ment op­tions and has the po­ten­tial to de­liv­er safer, con­sis­tent­ly man­u­fac­tured and more cost-ef­fec­tive cell im­munother­a­pies to pa­tients. [more in­for­ma­tion]
Numab Therapeutics
We are writ­ing the next chapter in can­cer im­munother­a­py by cre­at­ing mul­ti-spe­cif­ic anti­bodies that en­able the pur­suit of nov­el ther­a­peu­tic strate­gies. With our pro­pri­e­tary MATCH™ tech­nol­o­gy plat­form we are fu­el­ing a new wave of mul­ti-spe­cif­ic drug can­di­dates en­gi­neered with ver­satil­i­ty and de­vel­o­pa­bil­i­ty in mind. [more in­for­ma­tion]
Oculis Pharma
The com­pany's nov­el eye-drop treat­ments are based on its pro­pri­e­tary sol­u­bi­l­iz­ing nano­par­ti­cle (SNP) tech­nol­o­gy that im­proves both the abil­i­ty to for­mu­late drugs as eye drops and their bioa­vai­l­a­bil­i­ty in the eye tis­sues in­clud­ing both the front and the back of the eye, en­abling hos­pi­tals to pro­vide clients with tech­no­log­i­cal ad­vance­ment in oc­u­lar drug de­liv­ery. [more in­for­ma­tion]
OnKure Therapeutics, Inc.
De­vel­op­ing epi­ge­net­ic can­cer ther­a­pies in­clud­ing HDAC in­hibi­tors. Lead as­set OKI-179 is a class 1 HDAC in­hibi­tor in Ph 1. [more in­for­ma­tion]
Pipeline Therapeutics
The com­pany al­so has a port­fo­lio of pro­grams ad­dress­ing a range of neu­ro­log­i­cal di­s­or­ders, in­clud­ing de­vel­op­ment can­di­date PIPE-307 which is fo­cused on re­myeli­na­tion to treat mul­ti­ple scle­ro­sis. [more in­for­ma­tion]
Sensei Biotherapeutics
The com­pany is us­ing its pro­pri­e­tary drug dis­cov­ery plat­form, called SPIR­IT, to dis­cov­er and de­vel­op both vaccines and T-cell ther­a­pies, in­clud­ing SN­S301, its clin­i­cal stage can­cer vaccine, and SNS-723, its cell ther­a­py pro­gram in pre­clin­i­cal de­vel­op­ment for solid tu­mors and he­ma­to­log­i­cal can­cers. [more in­for­ma­tion]
Solebury Capital
Sole­bury Cap­i­tal LLC is a glob­al ad­vi­so­ry firm and reg­is­tered bro­k­er deal­er ex­clu­sive­ly fo­cused on the equi­ty cap­i­tal mar­kets. We pro­vide our cor­po­rate and fi­nan­cial spon­sor clients with in­de­pen­dent ad­vice, ex­pe­ri­enced judg­ment and tran­s­ac­tion ma­n­age­ment ser­vices – em­pow­er­ing them to make more ful­ly in­formed de­ci­sions at all points in the un­der­writ­ing pro­cess. [more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
SphingoTec GmbH
The tests are be­ing im­ple­ment­ed on the Com­pany’s own point-of-care im­munoas­say an­a­lyz­er plat­form ac­quired form Sam­sung in 2018 that is ful­ly de­vel­oped and was orig­i­nal­ly launched in 2012 and was sold more than 1,800 times since then. [more in­for­ma­tion]
Spruce Biosciences [SPRB] $370 MM MCap
The com­pany’s lead prod­uct can­di­date, til­dac­er­font, is an in­vesti­ga­tio­n­al oral drug that is be­ing eval­u­at­ed in studies for the treat­ment of con­geni­tal adre­nal hy­per­pla­sia (CAH). The com­pany al­so plans to eval­u­ate til­dac­er­font in other dis­eas­es im­pact­ed by el­e­vat­ed ACTH or adre­nal an­dro­gens. [more in­for­ma­tion]
TAE Life Sciences
TAE Life Sci­ences is an ear­ly-stage biotech­nol­o­gy com­pany de­vel­op­ing com­pre­hen­sive tar­get drugs and neu­tron tech­nol­o­gy prod­uct port­fo­lio to en­able next-gen­er­a­tion boron neu­tron cap­ture ther­a­py (BNCT) as a first-line treat­ment for pa­tients glob­al­ly, pro­vid­ing a paradigm shift in ra­di­a­tion ther­a­py [more in­for­ma­tion]
Teon Therapeutics
Pipe­line of next-gen­er­a­tion can­cer ther­a­peu­tics tar­get­ing GPCRs in­clud­ing a high­ly-spe­cif­ic A2B an­ta­g­on­ist and EP4 an­ta­g­on­ist, both slat­ed to en­ter Phase 1b trials in 2021. [more in­for­ma­tion]
Vaccitech Limited
Pro­pri­e­tary ChA­dOx (prime) and MVA (boost) tech­nol­o­gy plat­form in­duces and main­tains CD8+ T-cells at the max­i­mum lev­els pub­lished to date. Ph1/2 da­ta for HPV and HBV im­munother­a­pies ex­pect­ed 2H20. En­cour­ag­ing pros­tate can­cer, 5T4 im­munother­a­peu­tic da­ta re­cent­ly re­leased. Ph1/2 NS­CLC MAGE-NYE­SO im­munother­a­peu­tic en­ters clin­ic in Q1 2021. ChA­dOx COVID-19 vaccine out-li­censed to Ox­ford Uni/As­traZene­ca with post-pan­dem­ic rev­enue stream. $150M fund­ing at Jen­n­er In­sti­tute and com­pany raised $48M since for­ma­tion [more in­for­ma­tion]
ViaCyte, Inc.
The PEC-Di­rect™ prod­uct can­di­date de­liv­ers the pan­cre­at­ic pro­gen­i­tor cells in a non-im­muno­pro­tec­tive de­vice and is be­ing de­vel­oped for type 1 di­a­betes pa­tients who have hy­po­g­lycemia un­aware­ness, ex­treme glycemic la­bil­i­ty, and/or re­cur­rent se­vere hy­po­g­lycemic epi­sodes. [more in­for­ma­tion]
Viramal Limited
Vi­ra­mal is an emerg­ing spe­cial­ty phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of glob­al ther­a­peu­tics that im­prove the qual­i­ty of wo­m­en’s health world­wide. The com­pany is de­vel­op­ing in­no­va­tive prod­ucts that tar­get un­met ther­a­peu­tic ar­eas through the use of its unique phar­ma­ceu­ti­cal de­liv­ery plat­forms and tech­nolo­gies. [more in­for­ma­tion]
Vor Biopharma
Th­ese eH­SCs lead to gen­er­a­tions of new healthy blood cells and the eH­SCs can cont­in­ue func­tion­ing nor­mal­ly be­cause they are ef­fec­tive­ly hid­den from the ther­a­pies that tar­get the rel­e­vant pro­tein. In con­trast, dis­eased cells re­tain the tar­get pro­tein and are vul­n­er­able to at­tack. [more in­for­ma­tion]
Zikani Therapeutics
Zikani Ther­a­peu­tics is us­ing its in­no­va­tive chem­istry tech­nol­o­gy plat­form to de­vel­op nov­el Ri­bo­some Mo­d­u­lat­ing Agents (RMAs). Zikani’s TUR­BO-ZM plat­form al­lows rapid syn­th­e­sis of nov­el com­pounds that can be op­ti­mized to mo­d­u­late the hu­man ri­bo­some in a dis­ease spe­cif­ic man­n­er. [more in­for­ma­tion]